Sodium acid phosphate 700mg / Potassium dihydrogen phosphate 305mg tablets
Available from pharmacies, supermarkets, and retail outlets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Sodium acid phosphate + Potassium dihydrogen phosphate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 27 studies.
Reviews & meta-analyses: 2 · 1946–2026
Showing all 27 studies, sorted by most relevant.
J. Jerphagnon, S. K. Kurtz
Physical Review B, 1970
W. P. Mason
Physical Review, 1946
Seema Gosavi, Rushikesh Nanaware
Asian Journal of Pharmaceutical Analysis, 2024
Hegde NN, Somanatha H, Lakshmi V C, et al.
2026
studies suggest comparable or superior sealing ability relative to conventional calcium silicate cements, human clinical evidence is minimal or absent. Degradation and resorption profiles of MPCs may further affect their suitability as scaffolds in regenerative endodontics. Overall, MPCs represent promising investigational materials, yet claims regarding clinical readiness are premature. Careful evaluation of their physicochemical behaviour, biological safety, and practical handling is essential before consideration for routine clinical use.
Abstract licence: CC BY-NC-SA
Qinglong Huang, Su-Su Wang, Yongsheng Du, et al.
Materials, 2024
This study investigates the effects of phosphoric acid (H3PO4), potassium dihydrogen phosphate (KH2PO4) and sodium dihydrogen phosphate (NaH2PO4) admixtures on the setting time, compressive strength and water resistance of magnesium oxychloride cement (MOC). MOC samples incorporating different admixtures are prepared, and their hydration products and microstructures are studied via X-ray diffraction (XRD) and scanning electron microscopy (SEM). The results indicate that the addition of H3PO4, KH2PO4 and NaH2PO4 reduces the initial and final setting times and decreases the compressive strength. However, the compressive strength of MOC is higher than 30.00 MPa with the addition of 2.0 wt.% phosphoric acid and its phosphate after 14 days of air curing. The water resistance of modified MOC slurries is significantly improved. The softening coefficient of MOC with 2.0 wt.% H3PO4 is 1.2 after 14 days of water immersion, which is 3.44 times higher than that of the neat MOC. The enhancement in water resistance is attributed to the formation of amorphous gel facilitated by H3PO4, KH2PO4 and NaH2PO4. Furthermore, the improvement in water resistance is manifested as H3PO4 > KH2PO4 > NaH2PO4.
Abstract licence: CC BY
M.A. Shaymardanova, K. Mirzakulov, G. Melikulova, et al.
Chemical Problems, 2023
Xiaobo Zou, Lixiu Yan, Xiaofang Luo, et al.
MATEC Web of Conferences, 2023
A UPLC-MS/MS method was developed for simultaneous determination of 7 whitening ingredients: nicotinamide, kojic acid, Tranexamic acid, raspberry glycoside, azelaic acid, magnesium ascorbate phosphate and β-Arbutin in cosmetics. The whitening active components were extracted from cosmetics by supersonic extraction with sodium chloride and dichloromethane to disperse the sample, and supersonic extraction with 0.015 mol/L potassium dihydrogen phosphate solution purified by HLB solid phase extraction column, scanned and detected by electrospray ionization source with positive and negative ion alternate scanning mode and multiple reaction monitoring mode. The results showed that the whitening active ingredients were separated within 3 minutes, with a good linear relationship (R>0.999), and the detection limit was 0.10mg/kg~0.75mg/kg. The recoveries (n=6) were 78.84%-104.85%, and the RSDs were 0.24%-11.35%. This method is suitable for the rapid determination of whitening active ingredients in cosmetics.
Abstract licence: CC BY
Yanru Tao, Hua Zhao, Yujie Xiang, et al.
Journal of chromatographic science, 2024
- Mice, Inbred BALB C
- Mitoxantrone
- Limit of Detection
The concentration of mitoxantrone in the blood of mice was determined by a high-performance liquid chromatography-ultraviolet method with aloe-emodin as the internal standard. The separation was performed on a Hypersil BDS2 column (4.6 × 250 mm, 5 μm) as the analytical column, the mobile Phase A was acetonitrile, and B was 20-mM potassium dihydrogen phosphate (adding 1% triethylamine and adjusting the pH to 2.8 with phosphoric acid) and 4.6-mM sodium octyl sulfonate. The flow rate was 1.0 mL·min-1, the detection wavelength was 243 nm, the column temperature is 25 ± 5°C and the injection amount was 20 μL. Finally, the linear range of mitoxantrone was 5-200 μg·mL-1, and the correlation coefficient was r = 0.9999. The recovery rate of the method was 91.93-105.5%, and the extraction recovery rate was 91.45-105.5%. The intraday precision and interday precision were <3.29% (limit of detection = 0.3 μg·mL-1). The HPLC method established in this paper was simple, rapid, sensitive and accurate, and can be used to determine the content of mitoxantrone in mouse plasma after tail vein injection.
Abstract licence: Public domain
Badaka B, Badami V, Masreen J, et al.
2025
Dental enamel is susceptible to acid-induced demineralization and while fluoride treatments are effective, they have limitations such as superficial remineralization and risk of fluorosis. This in vitro study examined the remineralization potential of calcium phosphate (CaP) nanoparticles, bioactive glass (BAG) nanoparticles and nano-hydroxyapatite (nHAp) on artificially demineralized human enamel. Energy-dispersive X-ray spectroscopy and Vickers microhardness were used to assess the 60 premolars after they were prepared, separated into four groups (control, CaP, nHAp and BAG), demineralized and treated daily for seven days. All nanoparticle groups showed significant remineralization versus control, with nHAp achieving the highest hardness and Ca/P ratio, followed by BAG and CaP. Thus, we show nHAp as the most effective non-invasive remineralizing agent for early carious lesions.
Abstract licence: CC BY
Hiroaki Onoda, Mayu Matsubara
Materials Research Innovations, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.